AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05025865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
Study NCT05025865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be given in capsule form to study participants.
Study NCT06015659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zentalis
Description: Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
Study NCT06015659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
Study NCT05335447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG3667 capsule
Description: On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667
Study NCT05346848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of darolutamide and EBRT
Description: Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD
Study NCT05346848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Association of ADT and EBRT
Description: Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~* Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~* Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD
Study NCT06266299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK2269
Description: KK2269 administered intravenously
Study NCT06266299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: antineoplastic drug administered intravenously
Study NCT05316571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One 5-Minute Walking Bout Each Hour
Description: One 5-minute light intensity walking break per hour throughout the 4-hour SB condition
Study NCT04775173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Use of different doses of the same drug
Study NCT05316571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One 15-Minute Standing Bout Each Hour
Description: One 15-minute standing break per hour throughout the 4-hour SB condition
Study NCT05316571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour
Description: Two breaks per hour throughout the 4-hour SB condition, alternating between a 5-minute light intensity walking break and a 15-minute standing break
Study NCT04946084 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tympanocentesis
Description: When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.
Study NCT04946084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Phalangeal Swab and Wash
Description: Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.
Study NCT05316571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uninterrupted Sitting
Description: No breaks will be provided throughout the 4-hour SB condition. This will be used as the control condition
Study NCT04946084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw
Description: Venipuncture
Study NCT06024473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Transcranial Magnetic Stimulation
Study NCT06024473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS+iVCT
Description: Transcranial Magnetic Stimulation and immersive virtual reality
Study NCT04253626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol Injection [Feraheme]
Description: 510mg intravenous ferumoxytol
Study NCT04253626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: 325mg oral ferrous sulfate
Study NCT05999708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381406
Description: GSK4381406 will be administered.
Study NCT05999708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.
Study NCT05999708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin will be administered.
Study NCT05171413 — intervention group
Intervention type: OTHER
Intervention: Prediction model
Description: We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.
Study NCT04775173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Use of different doses of the same drug
Study NCT06420167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10mg orally once daily
Study NCT05050097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.
Study NCT05050097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered as an IV infusion.
Study NCT05050097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab will be administered subcutaneously.
Study NCT05050097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered orally.
Study NCT05050097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be self-administered orally.
Study NCT05293639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Field Ablation
Description: PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
Study NCT06212791 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self- Report Evaluation-Duke Activity Status Index
Description: Complete the Self- Report Evaluation-Duke Activity Status Index
Study NCT06212791 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire
Description: Complete the Self- Report Evaluation, Atrial Fibrillation Effect on Quality of Life Questionnaire
Study NCT06212791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise test (CPET)
Study NCT06212791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiogram
Description: Transthoracic echocardiogram at rest and immediately following peak exercise during CPET
Study NCT06212791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory cardiac rhythm assessment
Description: Ambulatory cardiac rhythm assessment
Study NCT06212791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance (CMR)
Description: Cardiovascular magnetic resonance (CMR) study at rest and during two stages of submaximal exercise (ExeCMR)
Study NCT05180058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrapping + Breastmilk Group
Description: Interventions applied during orogastric tube insertion
Study NCT04717414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Subcutaneous Injection
Study NCT04717414 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT05555160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC
Description: Peripheral central venous catheterization (PICC) is mainly applied to patients with medium and long-term intravenous infusion, infusion of stimulant drugs and intermittent infusion of chemotherapy drugs. It is a catheterization technology to place PICC through peripheral veins and make its tip reach the central vein
Study NCT06081829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Subjects will take 2 tablets (500 mg total) orally once daily.
Study NCT06650514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-103
Description: OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
Study NCT06095115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06095115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally
Study NCT06605079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex intervention
Description: A complex intervention is carried out in the intensive care unit. This includes:~* telemedical consultations by specialized palliative care experts from external institutions for the respective hospital staff~* the training of hospital staff in the intensive care unit in basic palliative care and~* the use of checklists for the early identification of eligible patients and the structured recording of palliative care needs.~The efficacy and cost-effectiveness of the complex intervention will be investigated using a controlled clinical trial in a cluster-randomized controlled design. In addition, as part of the multicenter clinical study in WP 2 staff, patients and relatives will also be surveyed.
Study NCT06605079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: No complex intervention is established, just routine procedures.
Study NCT06589024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Training on computerized exercises that targets processing speed, attention and executive function for about 36 minutes per session, 5 sessions per week for a total of 36 sessions.
Study NCT06571734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06571734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06571734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06571734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06589024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education
Description: Access to sleep hygiene education materials
Study NCT06655636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Assistance
Description: The device spring components will be tuned to produce an assistive supination torque on the forearm.
Study NCT06655636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Sham (Slack Springs)
Description: The device spring components will be tuned to slack springs to serve as a placebo. The user will think they are receiving forces but in reality the device will not be providing any forces.
Study NCT06571734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Given PO
Study NCT04850261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG Injection
Description: Ovulation will be induced by subcutaneous hCG injection
Study NCT06655636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device tuned to Anti-Assistance
Description: The device spring components will be tuned to produce a resistive supination torque on the forearm.
Study NCT06657976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Treadmill Exercise
Description: This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
Study NCT06657976 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control
Description: This group will attend weekly one-hour educational sessions either on Zoom or in-person for 12 weeks. These sessions are on topics of interest to the typical PAD patient and may be led by study staff, physicians, or other health care workers.
Study NCT06657976 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nitrate-Rich Beetroot Juice + supervised exercise therapy
Description: Participants randomized to this group will drink nitrate-rich beetroot juice while engaged in supervised exercise.
Study NCT06657976 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + supervised exercise therapy
Description: Participants randomized to this group will drink placebo while engaged in supervised exercise.
Study NCT06664034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component reproductive health care intervention
Description: The multi-component reproductive health care intervention includes:~1. Young cancer patients presenting to oncology visits will complete a clinic-based reproductive health needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future and ii) need for contraception.~2. Reproductive health patient navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's reproductive health needs, ii) provide individualized patient education and counseling on a) infertility risk related to cancer type and treatment and b) screening and management strategies for reproductive health needs, iii) provide support with the goal of engaging in goal-concordant reproductive health care.~3. Telehealth reproductive health consultation will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour.
Study NCT06604715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87562761
Description: JNJ-87562761 will be administered.
Study NCT05619432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMD: Immersive VR
Description: The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)
Study NCT06662188 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JAG201
Description: Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
Study NCT05202106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visits
Description: Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
Study NCT05202106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Afini App
Description: Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
Study NCT06612866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Keratin hydrolysate
Description: The clinical study will be conducted in two phases. The first phase will aim at characterizing the metabolites present in human serum after consumption of the Kera-Diet® ingredient and at determining the overall absorption peak of the tested ingredient. The second phase will involve collecting sera enriched with metabolites at the absorption peak, following the ingestion of the ingredient. Subsequently, the final objective will be to characterize the influence of these sera enriched with metabolites of interest on the behavior of human skin cell and intestinal epithelial cell cultures.
Study NCT06614504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying the nicotine content of cigarettes
Description: Altering the nicotine content of the tobacco research cigarettes
Study NCT06614504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying the nicotine content of e-cigarettes
Description: Altering the nicotine content of the research e-cigarettes
Study NCT06400719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT16
Description: Single intravenous administration of 300mg of AVT16
Study NCT00733915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)
Description: L.C.S. Complete mobile-bearing total knee system
Study NCT06608511 — intervention group
Intervention type: OTHER
Intervention: Blood draw for the laboratory assessment
Description: Participants will have 50 milliliters (3.5 tablespoons) of blood drawn
Study NCT06619782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Practice facilitation (PF) is a supplemental support to increase competence and and adoption of the National Institute of Mental Health (NIMH) youth suicide prevention. pathway in primary care. Practices will receive 6 months of PF which involves clinic- and provider- level data review and adoption data for the 5 components of the prevention pathway, clinical coaching around implementing the different components , logistical coaching in identifying multilevel contextual barriers to implementation and strategies to overcome them
Study NCT06619782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in National Institute of Mental Health Youth Suicide Prevention Pathway
Description: Training in the National Institute of Mental Health (NIMH) Youth Suicide Prevention Pathway involves a 2-hour in-person presentation created in consultation with NIMH, Zero Suicide and Substance Abuse and Mental Health Services Administration. It is delivered by a licensed professional counselor with content expertise to all primary care practice personnel involved in the prevention pathway. The first hour focuses on conducting Ask Suicide Screening Questions (ASQ) screening, identifying risk/protective factors, identifying warning signs and conducting a brief suicide safety assessment. The second hour covers safety planning, lethal means safety, behavioral health referrals and arranging follow-up. Didactic and interactive methods are used, including group discussion, activities, videos and case vignettes
Study NCT06619782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training in National Institute of Mental Health Youth Suicide Prevention Pathway
Description: Training in the National Institute of Mental Health (NIMH) Youth Suicide Prevention Pathway involves a 2-hour in-person presentation created in consultation with NIMH, Zero Suicide and Substance Abuse and Mental Health Services Administration. It is delivered by a licensed professional counselor with content expertise to all primary care practice personnel involved in the prevention pathway. The first hour focuses on conducting Ask Suicide Screening Questions (ASQ) screening, identifying risk/protective factors, identifying warning signs and conducting a brief suicide safety assessment. The second hour covers safety planning, lethal means safety, behavioral health referrals and arranging follow-up. Didactic and interactive methods are used, including group discussion, activities, videos and case vignettes
Study NCT04850261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafarelin nasal spray
Description: Ovulation will be induced by nasal application of Nafarelin
Study NCT06682702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNS Group
Description: ISST Schroth exercises are a model of exercise aimed at correcting scoliosis in three dimensions. Dynamic neuromuscular stabilization exercises, on the other hand, are designed to achieve sagittal stabilization by utilizing the stabilizing function of the thoracic diaphragm muscle.
Study NCT06682702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Group
Description: ISST Schroth exercises are a model of exercise aimed at correcting scoliosis in three dimensions.
Study NCT05584202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection